CompletedNot Applicable

Brazilian Reality of Hepatocellular Carcinoma

Brazil300 participantsStarted 2024-04-15

Plain-language summary

National, multicenter, retrospective, non-randomized observational study (Real World Evidence-RWE) with the purpose of analyzing the epidemiological profile of Hepatocellular Carcinomas (BCLC A, B or C), clinical management, progression profile and overall survival of castrated patients treated in national oncology care reference centers, within the last 6 years (between 2017 to 2022).

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male and female; * Above 18 years old; * Hepatocellular carcinoma diagnosis (confirmed by biopsy or imaging); Exclusion Criteria: * Fibrollamelar carcinoma, hepatoblastoma, intrahepatic cholangiocarcinoma, neuroendocrine tumors or other less common types of liver tumors; * Patients with incomplete staging data; * Patients with only 1 visit to the participating site healthcare service, with loss to follow-up prior to the second visit to the participating site healthcare service; * Previous treatment for hepatocellular carcinoma in another institution; * Treatment with investigational drugs in a clinical trial.

What they're measuring

Epidemiological profile and pathological staging

Timeframe: At first diagnosis and over 6 years (Time of retrospective observational analysis of the study)

Trial details

NCT IDNCT06230328

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-11-14

View on ClinicalTrials.gov More Hepatocellular Carcinoma trials